Drug Trial Radar · NCT07475559
JSKN016HC in Patients With Advanced or Metastatic Solid Malignant Tumors
Last checked: Nov 20, 2026Latest source record: Mar 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
42
Planned (sponsor's estimate)
Start
Mar 1, 2026
Primary completion
Jul 1, 2028
Study completion Jul 1, 2028
Sponsor
- Lead sponsor
- Jiangsu Alphamab Biopharmaceuticals Co., LtdIndustry
- Sponsor type
- Industry
- First posted
- Mar 16, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase I, open-label, multicenter, first-in-human study to evaluate the safety, tolerability, PK/pharmacodynamic (PD) characteristics, and anti-tumor activity of JSKN016HC in subjects with advanced malignant solid tumors.
Conditions
- Advanced Solid Tumor Malignancies
Interventions
JSKN016HCDrug
JSKN016HC is a subcutaneously injectable formulation of a bispecific ADC targeting HER3 and TROP2 (the main active ingredient is JSKN016).
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of dose-limiting toxicities (DLTs) in each dose group of JSKN016HCTime frame: Baseline up to 28 days after the first dose
- Frequency and severity of treatment-emergent adverse events (TEAEs), treatment-related adverse events (TRAEs), serious adverse events (SAEs), etc., during treatment with JSKN016HC;Time frame: Postdose of last participant up to 2 year
- MTD and/or RP2D of JSKN016HC.Time frame: Postdose of last participant up to 2 year
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Scientia Clinical Research Ltd
Sydney, New South Wales, Australia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.